HomeCompareCLVLF vs EPRT

CLVLF vs EPRT: Dividend Comparison 2026

CLVLF yields 0.39% · EPRT yields 3.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CLVLF wins by $287.0K in total portfolio value· pulled ahead in Year 7
10 years
CLVLF
CLVLF
● Live price
0.39%
Share price
$8.45
Annual div
$0.03
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$350.4K
Annual income
$233,845.04
Full CLVLF calculator →
EPRT
EPRT
● Live price
3.92%
Share price
$30.77
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63.4K
Annual income
$12,840.73
Full EPRT calculator →

Portfolio growth — CLVLF vs EPRT

📍 CLVLF pulled ahead of the other in Year 7

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCLVLFEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CLVLF + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CLVLF pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CLVLF
Annual income on $10K today (after 15% tax)
$32.77/yr
After 10yr DRIP, annual income (after tax)
$198,768.28/yr
EPRT
Annual income on $10K today (after 15% tax)
$332.87/yr
After 10yr DRIP, annual income (after tax)
$10,914.62/yr
At 15% tax rate, CLVLF beats the other by $187,853.66/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CLVLF + EPRT for your $10,000?

CLVLF: 50%EPRT: 50%
100% EPRT50/50100% CLVLF
Portfolio after 10yr
$206.9K
Annual income
$123,342.88/yr
Blended yield
59.62%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

CLVLF
No analyst data
Altman Z
21.3
Piotroski
5/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+15.4% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CLVLF buys
0
EPRT buys
0
No recent congressional trades found for CLVLF or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCLVLFEPRT
Forward yield0.39%3.92%
Annual dividend / share$0.03$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%29%
Portfolio after 10y$350.4K$63.4K
Annual income after 10y$233,845.04$12,840.73
Total dividends collected$320.5K$37.9K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: CLVLF vs EPRT ($10,000, DRIP)

YearCLVLF PortfolioCLVLF Income/yrEPRT PortfolioEPRT Income/yrGap
1$10,777$77.10$11,205$505.18$428.00EPRT
2$11,687$155.31$12,672$682.46$985.00EPRT
3$12,820$314.80$14,490$930.48$1.7KEPRT
4$14,363$645.46$16,786$1,282.69$2.4KEPRT
5$16,720$1,351.66$19,753$1,791.56$3.0KEPRT
6$20,831$2,941.08$23,677$2,541.64$2.8KEPRT
7← crossover$29,138$6,849.18$29,008$3,672.99+$130.00CLVLF
8$49,086$17,907.69$36,463$5,425.08+$12.6KCLVLF
9$108,908$56,386.61$47,238$8,221.57+$61.7KCLVLF
10$350,377$233,845.04$63,385$12,840.73+$287.0KCLVLF

CLVLF vs EPRT: Complete Analysis 2026

CLVLFStock

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke increased and prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited t to treat EPP patients with SCENESSE under a named patient program in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.

Full CLVLF Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this CLVLF vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CLVLF vs SCHDCLVLF vs JEPICLVLF vs OCLVLF vs KOCLVLF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.